MenACWY vaccination campaign for adolescents in the Netherlands: Uptake and its determinants.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
de Oliveira Bressane Lima, Priscilavan Lier, Alies
de Melker, Hester
Ferreira, José A
van Vliet, Hans
Knol, Mirjam J
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
MenACWY vaccination campaign for adolescents in the Netherlands: Uptake and its determinants.Published in
Vaccine 2020; 38(24):5516-24PMID
32593605ae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2020.05.087
Scopus Count
Collections
Related articles
- A novel measles outbreak control strategy in the Netherlands in 2013-2014 using a national electronic immunization register: A study of early MMR uptake and its determinants.
- Authors: Nic Lochlainn LM, Woudenberg T, van Lier A, Zonnenberg I, Philippi M, de Melker HE, Hahné SJM
- Issue date: 2017 Oct 13
- Meningococcal W135 Disease Vaccination Intent, the Netherlands, 2018-2019.
- Authors: de Vries M, Claassen L, Te Wierik MJM, Coban F, Wong A, Timmermans DRM, Timen A
- Issue date: 2020 Jul
- Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
- Authors: Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ
- Issue date: 2013
- Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
- Authors: van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM
- Issue date: 2017 Aug 24
- Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
- Authors: Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N
- Issue date: 2013 May